Your DeepTech Startup Isn't Failing at Science. It's Failing at Sequence

There is a graveyard no one talks about. 

It doesn't appear in VC portfolios. It's not captured in accelerator graduation rates. It sits quietly between the lab and the market, and it is where some of the most consequential science of our generation is buried.

We call it the Innovation Valley of Death. But that phrase has become so overused, so casually referenced in pitch decks and policy papers, that we've lost sight of what it actually means: a structured, systemic failure to convert verified science into economic value.

In 2026, that failure is no longer acceptable. And the ecosystem enabling it deserves scrutiny.

The problem isn't the science. It's the sequence

The commercialisation gap in DeepTech isn't about weak research; it's about the brutal transition from intellectual property ready for market to actual customer acquisition. The chasm lies in getting to market when there's a validated technology but no clear commercial pathway. (Read more on -https://www.afcea.org/signal-media/technology/valley-death-phase-necessary)

Here's what the data tells us: DeepTech now accounts for roughly 20% of global VC funding, up from around 10% a decade ago. In Europe alone, it attracts 44% of all technology investment. Capital is not the problem at the macro level. The problem is where that capital lands and where it doesn't. (Researched data from - https://www.startus-insights.com/innovators-guide/deep-tech-market-report/)

DeepTech startups don't face one Valley of Death. They face multiple: the Initial commercialisation gap before a viable prototype exists, the Post-Seed Capital crunch, where companies with 10–15 employees are too early for institutional investors, and the Market validation cliff, where technology that received real investment turns out to have no viable market fit. Fedtech

Most ecosystems are designed to fund TRL 1–3 (proof of concept) and TRL 7+ (near-commercial). The wasteland between TRL 4 and TRL 7, where a technology is validated but not yet market-demonstrable, remains structurally underfunded.

The Commercialisation Readiness Stack

DeepTech has traditionally relied on TRL alone to assess maturity. That's insufficient.

What DeepTech founders actually need is a Commercialisation Readiness Stack, a layered framework that runs four parallel tracks simultaneously, not sequentially:

• TRL - Technology maturity

• MRL - Manufacturing scalability

• RRL - Regulatory pathway clarity

• CRL - Customer Readiness Level (market pull, not just market size)

Most founders nail TRL while neglecting MRL and CRL entirely. They arrive at a Series A with a working prototype, no manufacturing plan, and a customer pipeline built on letters of intent from people who attended their demo day.

Investors then walk away, not because the science is weak, but because the founder hasn't demonstrated commercial logic, only technical achievement.

The policy layer is finally catching up, but unevenly

Governments are beginning to architect around this gap. The European Innovation Council allocated EUR 300M for STEP Scale Up in 2026, specifically to support large DeepTech funding rounds at later stages. Programs like the Seeds of Bravery program targets TRL 7+ companies with grants of up to EUR 50,000. These are directionally correct but operationally thin, as grants at this scale don't move the needle for hardware-intensive DeepTech requiring years of manufacturing validation. (Read more on: StartUs Insights)

Relatively new DeepTech ecosystems like India on the other hand are responding to this challenge differently. The Indian government has launched a new National Technology Readiness Assessment Framework (NTRAF), open for consultation through January 2026, designed to provide an objective methodology for assessing technologies from TRL 1 through TRL 9, with explicit acknowledgment that the 'Valley of Death' between TRL 4 and TRL 7 is where funding dries up due to perceived risk. India's policymakers are beginning to design funding instruments around this gap.

What founders and investors must recalibrate?

Founders must stop measuring progress by TRL alone. Build your commercialization narrative around the full stack: manufacturing plan, regulatory sequence, and a credible first customer (not a reference customer, an anchor customer with budget authority). The science earns you the room. The commercial logic earns you the check.

For investors, the most defensible entry point in DeepTech is not TRL 3 (too early, too much technical risk) or TRL 7+ (too late, too expensive). It's TRL 5–6, where technical validation exists but commercial architecture is still being designed. That's where structured capital paired with operational expertise creates asymmetric returns.

For ecosystem builders, the real leverage point is not more pitch competitions or demo days. It's building what we call Commercialisation Bridges, structured programs that sit between university tech transfer offices and Series A investors, focused exclusively on MRL and CRL development over a 12–18 month window.

The ecosystems that win the next decade won't be the ones that produce the most breakthroughs. They'll be the ones that build the most rigorous bridges from lab to ledger.

"Science without commercial architecture is just an expensive curiosity."

StartupBay is a tech-first accelerator that supports the DeepTech startups and ecosystem partners as a commercialisation bridge across Europe and Southeast Asia